Oncotarget

Research Papers:

ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients

Ziyu Li, Xiaofang Xing, Fei Shan, Shuangxi Li, Zhongwu Li, Aitang Xiao, Zhaodong Xing, Kan Xue, Zhemin Li, Ying Hu, Yongning Jia, Rulin Miao, Lianhai Zhang, Zhaode Bu, Aiwen Wu and Jiafu Ji _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:55449-55457. https://doi.org/10.18632/oncotarget.10961

Metrics: PDF 1602 views  |   HTML 1965 views  |   ?  


Abstract

Ziyu Li1,*, Xiaofang Xing2,*, Fei Shan1, Shuangxi Li1, Zhongwu Li3, Aitang Xiao1, Zhaodong Xing1, Kan Xue1, Zhemin Li1, Ying Hu4, Yongning Jia1, Rulin Miao1, Lianhai Zhang1, Zhaode Bu1, Aiwen Wu1, Jiafu Ji1,2,3

1Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China

2Department of Gastrointestinal Translational Research, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China

3Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China

4Tissue Bank, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China

*These authors contributed equally to this work

Correspondence to:

Jiafu Ji, email: jiafuj@hotmail.com

Keywords: ABCC2, rs717620, gastric cancer, neoadjuvant chemotherapy, overall survival

Received: February 03, 2016     Accepted: June 29, 2016     Published: July 30, 2016

ABSTRACT

Several studies have evaluated the efficacy of neoadjuvant treatment using oxaliplatin and fluoropyrimidines in advanced gastric cancer (GC). However, preoperative biomarkers predictive of clinical outcome remain lacking. We examined polymorphisms in the MTHFR, DPYD, UMPS, ABCB1, ABCC2, GSTP1, ERCC1, and XRCC1 genes to evaluate their usefulness as pharmacogenetic markers in a cohort of 103 GC patients treated with preoperative chemotherapy. DNA was extracted from peripheral blood cells, and the genotypes were analyzed using a SNaPShotTM assay, polymerase chain reaction amplification, and sequencing. The ABCC2-24C > T (rs717620) genotype was associated with pathologic response to neoadjuvant chemotherapy. Patients with the TT and TC genotypes responded to neoadjuvant chemotherapy 3.80 times more often than those with the CC genotype (95% CI: 1.27–11.32). Patients with the CC genotype also had poorer outcomes than those with other genotypes. Thus, ABCC2-24C > T polymorphism may help to predict the response to preoperative chemotherapy in GC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10961